Pfizer touts successor to Prevnar 13

Phase 2 data showed Pfizer's experimental pneumococcal vaccine to be safe, boosting confidence in what Pfizer hopes will be a follow-on to Prevnar 13.

By Andrew Dunn • Sept. 9, 2019

After scandal, Novartis pledges faster action on data integrity

CEO Vas Narasimhan committed to informing the FDA within five business days of any credible data integrity issues tied to a pending drug application.

By Ned Pagliarulo • Sept. 9, 2019

Explore the Trendline➔

Alzheimer's disease

Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.

By BioPharma Dive staff

Cancer drug data back up Lilly's Loxo buyout

Updated study results show striking efficacy for LOXO-292 in an uncommon form of lung cancer, clearing the path for Lilly to file for approval this year. 

By Ned Pagliarulo • Sept. 9, 2019

Mallinckrodt plunges after report it's mulling bankruptcy amid opioid trial

Staring down more than 2,000 opioid lawsuits, the pharma has maxed out its borrowing capacity, raising the possibility of bankruptcy, per Bloomberg. 

By Andrew Dunn • Sept. 5, 2019

Pharma's reputation among Americans sinks to lowest level in decades: poll

According to Gallup, Americans even view the federal government more favorably than biopharma, which ranks as the most poorly regarded industry.

By Kristin Jensen • Sept. 4, 2019

Skyrizi looks ready to soar after strong launch

Dermatologists expect Skyrizi prescriptions to accelerate, according to a new survey that has some analysts now forecasting $300 million in 2019 sales for the psoriasis drug.

By Jacob Bell • Sept. 4, 2019

Novartis vies for multiple sclerosis dominance with Arzerra trial

The repurposed cancer drug is aiming at Roche's Ocrevus, but an upcoming full data presentation will tell MS specialists more about its promise.

By Jonathan Gardner • Aug. 30, 2019

AbbVie ends Rova-T research after another study setback

A string of clinical failures derailed AbbVie's ambitions for the cancer drug, which was once predicted to earn billions of dollars in peak sales.

By Andrew Dunn • Aug. 29, 2019

Purdue offering as much as $12 billion to settle opioid claims: report

The Oxycontin maker would reportedly declare Chapter 11 bankruptcy, becoming a public trust in which profits from drug sales would go to plaintiffs.

By Ned Pagliarulo • Aug. 28, 2019

Biopharma jobs boom in Massachusetts, though challenges still exist

Many more jobs have opened up in R&D than in manufacturing, which saw growth of just 1% between 2017 and 2018.

By Jacob Bell • Aug. 27, 2019

Oklahoma judge orders J&J pay $572M in landmark opioid case

At issue was J&J's marketing of opioids Duragesic and Nucynta, as well as its supplying of API to other manufacturers via subsidiaries Noramco and Tasmanian Alkaloids.

By Ned Pagliarulo • Aug. 26, 2019